Vaccines: Pfizer, Biotech report booster shot effectiveness and trials on combined Covid and flu vaccine

Pfizer, BioNTech say bivalent COVID-19 booster shot performs better against BA.5 omicron subvariant Pfizer and BioNTech said that updated data from a Phase 2-3 clinical trial shows the bivalent booster performed better against the BA.4 and BA.5 omicron subvariants. ABC News ABC News

...

According to a joint press release, updated data from a Phase 2-3 clinical trial shows the Pfizer-BioNTech bivalent vaccine produced antibody responses against the BA.4 and BA.5 omicron subvariants that were three- to four-fold higher, compared with the original formula, when measured in adults approximately one month after receiving a booster dose. The safety and tolerability profile of the bivalent booster remains favorable and similar to the original vaccine, Pfizer and BioNTech said. ...

Pfizer, BioNTech launch phase 1 trial on combined COVID-19 and flu vaccine Pfizer and BioNTech announced Thursday that they have started a phase 1 trial on a combination COVID-19 and influenza vaccine. ABC News ABC News